clinical trial · NCT07383506
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
PIK3CA MutationsAdvanced Solid Tumors, AdultEndometrial CancerHR Positive/HER-2 Negative Breast CancerHER2-low Breast CancerCGT6297
brief summary
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations
started
Jun 1, 2026
primary completion
Jul 1, 2029
completion
Aug 1, 2029
last updated
Jul 1, 2026
official title
A Study of a Mutant-Selective Inhibitor, CGT6297, in Patients With Advanced Solid Tumors Harboring PIK3CA Mutations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol